Mechanism of action
Caffeine exerts its primary pharmacological effects through competitive antagonism of adenosine receptors, particularly the A1 and A2A subtypes. Adenosine normally promotes sedation, vasodilation, and decreased neuronal firing; by blocking these receptors, caffeine produces CNS stimulation, increased alertness, and vasoconstriction (except in coronary vessels where it causes vasodilation).
Additional mechanisms
- Phosphodiesterase inhibition: At higher concentrations, caffeine inhibits phosphodiesterase enzymes, leading to increased intracellular cAMP and enhanced calcium release from the sarcoplasmic reticulum. This contributes to positive inotropic and chronotropic cardiac effects and bronchodilation.
- Respiratory center stimulation: Caffeine increases medullary respiratory center sensitivity to carbon dioxide, making it effective for apnea of prematurity.
- Neurotransmitter modulation: Adenosine blockade indirectly increases dopamine, norepinephrine, and glutamate release in certain brain regions.
The cerebral vasoconstriction produced by caffeine is the basis for its use in treating certain types of headaches, particularly when combined with analgesics.
- Caffeine is first-line therapy for apnea of prematurity and reduces need for mechanical ventilation
- Mechanism: competitive antagonist at adenosine A1 and A2A receptors in the CNS
- Neonatal half-life is 50-100 hours vs. 3-7 hours in adults due to immature CYP1A2
- Caffeine antagonizes adenosine; patients must avoid caffeine before adenosine stress tests
- Withdrawal headache typically begins 12-24 hours after cessation and peaks at 20-48 hours
- Ciprofloxacin and fluvoxamine inhibit CYP1A2, increasing caffeine levels and toxicity risk
- Caffeine enhances analgesic efficacy by approximately 40% in headache treatment
- Chronic daily use of caffeine-containing analgesics can cause medication-overuse headache
Indications
Neonatal apnea
Caffeine citrate is first-line therapy for apnea of prematurity in infants born at less than 35 weeks gestation. It reduces the frequency of apneic episodes, decreases the need for mechanical ventilation, and improves long-term neurodevelopmental outcomes. The CAP trial demonstrated reduced rates of bronchopulmonary dysplasia and cerebral palsy with caffeine therapy.
Headache treatment
Caffeine is used as an adjuvant analgesic in combination formulations for tension-type and migraine headaches. It enhances the efficacy of acetaminophen and aspirin by approximately 40% and may abort early migraine through cerebral vasoconstriction.
CNS stimulation
Caffeine is used off-label to:
- Promote wakefulness and combat fatigue
- Enhance cognitive performance and alertness
- Treat post-dural puncture (spinal) headache
- Counteract respiratory depression in certain clinical contexts
Diagnostic use
Caffeine is occasionally used in pharmacological stress testing as an alternative to adenosine, though adenosine itself is more commonly employed.
Pharmacokinetics
- Absorption: Rapidly and completely absorbed from the gastrointestinal tract; peak plasma levels occur within 30-60 minutes of oral administration.
- Distribution: Widely distributed throughout body water and tissues; crosses the blood-brain barrier and placenta; volume of distribution approximately 0.6 L/kg.
- Metabolism: Primarily hepatic via CYP1A2 to paraxanthine (major metabolite), theobromine, and theophylline. Neonates have immature CYP1A2 activity, resulting in a much longer half-life (50-100 hours vs. 3-7 hours in adults).
- Elimination: Renal excretion of metabolites; less than 3% excreted unchanged in adults. Half-life is prolonged in pregnancy (up to 15 hours in the third trimester) and in patients with liver disease.
Special populations
Neonates: Decreased clearance and prolonged half-life due to immature hepatic enzymes; therapeutic monitoring may be warranted.
Smokers: CYP1A2 induction leads to increased caffeine metabolism and reduced half-life.
Pregnancy: Decreased clearance, especially in the third trimester; caffeine crosses the placenta freely.
Adverse effects
Cardiovascular
- Tachycardia and palpitations
- Increased blood pressure (usually modest, 5-10 mmHg)
- Arrhythmias in susceptible individuals
- Exacerbation of coronary artery disease symptoms
Central nervous system
- Insomnia and disrupted sleep architecture
- Anxiety, nervousness, restlessness
- Tremor
- Headache (especially with withdrawal)
Gastrointestinal
- Nausea and dyspepsia
- Increased gastric acid secretion
- Diarrhea
- Gastroesophageal reflux
Renal
- Diuresis (mild; due to adenosine antagonism in renal tubules)
Metabolic
- Hyperglycemia (increased epinephrine release)
- Hypokalemia (intracellular shift)
Neonatal-specific effects
- Tachycardia
- Feeding intolerance
- Jitteriness
- Rarely, seizures at toxic levels
Withdrawal syndrome
Abrupt cessation after chronic use produces headache (most common), fatigue, irritability, difficulty concentrating, and dysphoric mood. Symptoms typically begin 12-24 hours after last use and peak at 20-48 hours.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to caffeine or other methylxanthines
Relative contraindications and cautions
- Cardiac arrhythmias: Caffeine may precipitate or worsen tachyarrhythmias.
- Severe hypertension: May acutely raise blood pressure.
- Anxiety disorders: Can exacerbate symptoms.
- Peptic ulcer disease: Increases gastric acid secretion.
- Seizure disorders: Lowers seizure threshold at high doses.
Pregnancy and lactation
Pregnancy: Crosses the placenta; high intake (>300 mg/day) has been associated with increased risk of miscarriage and low birth weight in epidemiological studies. Moderate use (less than 200 mg/day) is generally considered acceptable. Fetal metabolism of caffeine is minimal.
Lactation: Excreted in breast milk; concentrations are approximately 50% of maternal plasma levels. Excessive maternal intake may cause irritability and poor sleep in breastfed infants.
Dependence potential
Caffeine produces physical dependence with regular use. Tolerance develops to some effects (e.g., sleep disruption, diuresis) but not others (e.g., CNS stimulation). It is not classified as a controlled substance.
Drug interactions
CYP1A2 interactions
- Inhibitors (e.g., ciprofloxacin, fluvoxamine, oral contraceptives): Decrease caffeine metabolism, increasing plasma levels and risk of toxicity.
- Inducers (e.g., cigarette smoking, carbamazepine, rifampin): Increase caffeine metabolism, reducing plasma levels and effects.
Pharmacodynamic interactions
- Sympathomimetics (e.g., ephedrine, pseudoephedrine): Additive CNS and cardiovascular stimulation; increased risk of hypertension and arrhythmias.
- Adenosine: Caffeine antagonizes the effects of adenosine used for cardiovascular stress testing or arrhythmia termination. Patients should abstain from caffeine for 12-24 hours before adenosine stress tests.
- Lithium: Caffeine increases lithium renal clearance; abrupt caffeine cessation may increase lithium levels and risk of toxicity.
- Clozapine: Caffeine inhibits CYP1A2, potentially increasing clozapine levels.
- Theophylline: Additive methylxanthine effects and toxicity risk.
- MAO inhibitors: Theoretical risk of hypertensive crisis due to enhanced catecholamine release, though clinically rare.
Other interactions
- Alcohol: Caffeine may mask the sedative effects of alcohol, leading to underestimation of intoxication.
- Quinolone antibiotics: Particularly enoxacin and ciprofloxacin significantly inhibit caffeine metabolism.
Clinical pearls
- Apnea of prematurity: Caffeine citrate has a wider therapeutic window and longer half-life than theophylline, making it safer and requiring less frequent dosing and monitoring. It is the methylxanthine of choice for neonatal apnea.
- Post-dural puncture headache: Intravenous caffeine sodium benzoate (500 mg) can provide rapid relief. The mechanism involves cerebral vasoconstriction and increased CSF production.
- Caffeine content: A standard cup of coffee contains 80-100 mg of caffeine; energy drinks may contain 50-300 mg per serving. Medications containing caffeine typically provide 30-200 mg per dose.
- Toxicity: Caffeine toxicity produces symptoms similar to sympathomimetic toxidromes, including tachycardia, hypertension, agitation, tremor, and in severe cases, seizures and arrhythmias. Levels above 15 mg/L are considered toxic. Treatment is supportive, with benzodiazepines for agitation and seizures.
- Withdrawal headache: Responds to caffeine reintroduction or NSAIDs. Tapering caffeine over 1-2 weeks minimizes withdrawal symptoms.
- Genetic variation: CYP1A2 polymorphisms affect caffeine metabolism; slow metabolizers may experience more pronounced effects and adverse reactions.
- Sports performance: Caffeine enhances endurance performance and is no longer on the World Anti-Doping Agency prohibited list. Effects are dose-dependent, with 3-6 mg/kg providing ergogenic benefits.
- Differential diagnosis: Patients presenting with anxiety, palpitations, or insomnia should be asked about caffeine intake, as excessive consumption is a common and reversible cause.
- Headache paradox: While caffeine can treat headaches acutely, chronic daily use can lead to medication-overuse headache (formerly called rebound headache). Caffeine-containing analgesic combinations should not be used more than 2-3 days per week.
Practice questions
1. A 28-day-old former 29-week preterm infant is being treated in the NICU for apnea of prematurity. Despite receiving caffeine citrate therapy, the nurse reports multiple apneic episodes overnight requiring stimulation. The infant's heart rate is 180/min. Which of the following pharmacokinetic properties of caffeine best explains the need for careful dose adjustment in this patient?
2. A 45-year-old woman presents to the emergency department with complaints of palpitations and anxiety. She reports drinking 6-8 cups of coffee daily for the past 10 years. Her physician recently prescribed ciprofloxacin for a urinary tract infection, which she started 3 days ago. Her heart rate is 110/min and blood pressure is 145/92 mmHg. Which of the following best explains her current symptoms?
3. A 62-year-old man with a history of coronary artery disease is scheduled for pharmacological stress testing to evaluate chest pain. His medications include aspirin, atorvastatin, and metoprolol. He reports drinking 3 cups of coffee each morning, including on the day of the test. Administration of which of the following agents is most likely to be ineffective due to his caffeine consumption?
Frequently asked questions
How does caffeine work?
Caffeine works primarily by competitively blocking adenosine receptors (A1 and A2A subtypes) in the central nervous system. Adenosine normally promotes sedation and decreased neuronal activity, so blocking these receptors results in increased alertness, wakefulness, and CNS stimulation. At higher concentrations, caffeine also inhibits phosphodiesterase enzymes, leading to increased cAMP levels, which contributes to cardiac stimulation and bronchodilation. In neonates, caffeine stimulates the medullary respiratory center, increasing sensitivity to carbon dioxide and reducing apneic episodes.
What are the side effects of caffeine?
Common side effects of caffeine include insomnia, nervousness, restlessness, tachycardia, palpitations, increased blood pressure, tremor, and gastrointestinal upset including nausea and diarrhea. At higher doses, caffeine can cause anxiety, headaches, and cardiac arrhythmias in susceptible individuals. Chronic use leads to physical dependence, and abrupt cessation produces withdrawal symptoms, most notably headache beginning 12-24 hours after the last dose. In neonates treated for apnea, side effects may include tachycardia, feeding intolerance, and jitteriness.
Is caffeine a controlled substance?
No, caffeine is not a controlled substance under the US Controlled Substances Act or international drug control conventions. While caffeine does produce physical dependence and tolerance with regular use, and withdrawal symptoms upon cessation, it is not classified as having significant abuse potential warranting scheduling. It is widely available without prescription in foods, beverages, and over-the-counter medications. However, pure caffeine powder sold as a supplement has led to fatal overdoses and is subject to FDA regulatory actions.
Why is caffeine used for apnea of prematurity?
Caffeine citrate is first-line therapy for apnea of prematurity because it stimulates the medullary respiratory center, increasing its sensitivity to carbon dioxide and reducing the frequency of apneic episodes. It has several advantages over the alternative methylxanthine, theophylline: a wider therapeutic window, longer half-life allowing once-daily dosing, fewer side effects, and less need for therapeutic drug monitoring. Landmark trials have shown that caffeine reduces the need for mechanical ventilation and improves long-term neurodevelopmental outcomes, including reduced rates of cerebral palsy and bronchopulmonary dysplasia.
Caffeine vs theophylline — what is the difference?
Both caffeine and theophylline are methylxanthine derivatives that act primarily through adenosine receptor antagonism and phosphodiesterase inhibition. However, caffeine has a much wider therapeutic window and is safer, particularly in neonates, where it is preferred for treating apnea of prematurity. Theophylline has a narrow therapeutic index requiring frequent drug level monitoring and causes more frequent adverse effects including serious arrhythmias. Theophylline is still occasionally used for asthma and COPD, though it has largely been replaced by safer alternatives. Caffeine's longer half-life in neonates (50-100 hours) allows once-daily dosing, whereas theophylline requires more frequent administration.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06BC01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.